// App-Quantinova.ai

OT3-2-01 : IMPACT: IMaging PAtients for Cancer drug selecTion Metastatic breast cancer (MBC)

Researchers

Presenter

  • Bensch F

Principal Investigators

  • Brouwers A

  • Glaudemans A

  • Menke-van der Hoeven van Oordt W

  • Verheul H

  • Hoekstra O

  • Janssen J

  • Huisman M

  • Elias S

  • Moons C

  • de Vries L

  • Schrder Cde Jong Jde Vries E

  • van de Graaf W

  • Boon E

  • Oyen W

  • de Geus-Oei L-F

  • Visser E

  • van Helden E

Medical Centers

  • Radboud University Medical Center, Njmegen, Netherlands

  • University Medical Center Groninge, NetherlandsVU Medical Center, Amsterdam, Noord-Holland, NetherlandsUniversity Medical Center, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • 18F-fluorodeoxyglucose

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Circulating DNA

Drug/Treatment

  • Trastuzumab

  • Fludeoxyglucose (18F)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved